Blockade of PD-1 or PD-L1 activities may provide an optional management approach for PD-L1-overexpressing tumors, e.g., NSCLC with EGFR mutation, that has EGFR-TKI resistance [19]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.